The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, cilt.47, sa.3, ss.891-898, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 47 Sayı: 3
- Basım Tarihi: 2025
- Doi Numarası: 10.1002/hed.27976
- Dergi Adı: HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
- Sayfa Sayıları: ss.891-898
- Anahtar Kelimeler: indolent lymphoma, lymphoma, orbital lymphoma, radiotherapy, rituximab
- Hacettepe Üniversitesi Adresli: Evet
Özet
BackgroundThis study evaluates the oncological outcomes and toxicities of indolent ocular adnexal and orbital lymphomas (OOLs) treated with radiotherapy (RT) +/- systemic therapy.MethodsA retrospective analysis of 44 patients with indolent OOLs treated with RT was conducted.ResultsMost patients (87%) had early-stage disease. Treatment involved RT alone (34%) or RT + systemic therapy (66%). The median RT dose was 30 Gy, with a median follow-up of 45 months. Local and systemic recurrence rates were 4% and 9%, respectively. Five-year overall and disease-free survival (DFS) rates were 96.2% and 83.6%. Early-stage patients showed similar DFS rates regardless of whether they received RT alone or RT plus systemic therapy. No grade 3 RT-related toxicity occurred, but systemic therapy led to grade 3 toxicity in 17% of patients.ConclusionsRT is essential for treating indolent OOLs, and combination with systemic therapies does not enhance outcomes for early-stage patients.